Business Context and Reporting Period
Company: AngioDynamics, Inc. (ANGIODYNAMICS INC)
Filing Type: Form 8-K (Current Report)
Report Date: October 2, 2025
Reporting Period: Fiscal First Quarter ended August 31, 2025
This filing serves to announce the issuance of a press release and presentation slides regarding the company's financial results for the specified quarter. The filing itself does not contain the detailed financial tables but references them as Exhibits 99.1 and 99.2.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical data. The following metrics are referenced as being available in the attached exhibits but are not present in this text:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Note: Specific values for revenue, profit, cash flow, margins, debt, and liquidity are not available in the source text provided.
Material Changes
The filing text does not provide specific comparative data or describe material changes versus the prior comparable period. It only confirms that results for the fiscal first quarter ended August 31, 2025, have been announced.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document includes a standard disclaimer that it contains forward-looking statements regarding future financial position, results of operations, cash flows, business strategy, and growth opportunities. These statements are subject to risks and uncertainties and are not guarantees of future performance.
Identified Risks and Contingencies: The filing lists numerous factors that could cause actual results to differ materially from expectations, including:
- Scale and scope of the COVID-19 global pandemic.
- Product development capabilities and technological advances by competitors.
- Intellectual property infringement or assertions thereof.
- Competition from entities with substantially greater resources.
- Regulatory actions by the FDA or other agencies.
- Health care reforms and government regulations.
- Results of pending or future clinical trials.
- Economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges.
- On-going litigation.
- Challenges with third-party distributors, joint venture partners, or collaborators.
- Product recalls and product liability claims.
- Changes in key personnel.
- Foreign currency exchange rate fluctuations.
- Pricing effects from group purchasing organizations.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and EPS figures for the quarter ended August 31, 2025.
- Review Exhibit 99.2 (Presentation Slides) for management's commentary on operational highlights and strategic initiatives.
- Verify year-over-year and quarter-over-quarter growth rates in the attached exhibits to assess material changes.
- Check the company's most recent Form 10-K for the year ended May 31, 2025, for detailed risk factor disclosures referenced in this filing.
- Confirm if any specific guidance for the full fiscal year was updated in the press release.